

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;

(b) complements of the sequences provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;

(d) sequences that hybridize to a sequence provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431, under highly stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;

(f) sequences having at least 90% identity to a sequence of SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431; and

(g) degenerate variants of a sequence provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431.

2. (Canceled)

3. (Original) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.

5.-10 (Canceled)

11. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising the isolated polynucleotide according to claim 1. ~~selected from the group consisting of:~~

- ~~(a) — polypeptides according to claim 2;~~
- ~~(b) — polynucleotides according to claim 1;~~
- ~~(c) — antibodies according to claim 5;~~
- ~~(d) — fusion proteins according to claim 7;~~
- ~~(e) — T cell populations according to claim 10; and~~
- ~~(f) — antigen presenting cells that express a polypeptide according to claim 2.~~

12. (Original) A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 11.

13. (Original) A method for the treatment of a lung cancer in a patient, comprising administering to the patient a composition of claim 11.

14.-17 (Canceled)